Table 5.

Factors that increase the clinical efficacy of AIT ^{a, b}

Short duration of disease

Minor involvement of the lower airways

Age (the EMA PDCO recommends that therapy not be commenced before the age of 5 years)

Good compliance and adherence

A high cumulative AIT dose

^a The more of these points that apply, the higher the probability that administration of AIT will reduce symptoms and medication use, as well as decrease the likelihood of allergic march – the development of bronchial asthma and broadening of the allergen spectrum. ^b only valid for inhalant allergens